• / Free eNewsletters & Magazine
  • / My Account
Home>Biodesix Announces Inclusion of VeriStrat in Updated NCCN Guidelines

Biodesix Announces Inclusion of VeriStrat in Updated NCCN Guidelines

3party Content

Fri, 24 Oct 2014

Biodesix Inc., a molecular diagnostics company dedicated to advancing precision medicine and improved patient care, today announced that its VeriStrat® blood-based prognostic and predictive proteomics test has been approved for inclusion in the National Comprehensive Cancer Network Clinical
Upcoming Events
Conferences
Webinars

©2014 Morningstar Advisor. All right reserved.